TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has issued an update.
Shanghai Henlius Biotech, Inc. announced that its HANSIZHUANG (serplulimab injection), in combination with chemotherapy, has received Breakthrough Therapy Designation from China’s National Medical Products Administration for the treatment of gastric cancer. This designation highlights the potential impact of HANSIZHUANG on cancer treatment and strengthens the company’s position in the oncology market, potentially benefiting stakeholders through enhanced treatment options and market expansion.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$66.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, specializing in the development of innovative monoclonal antibodies. The company focuses on treatments for various cancers, including lung, esophageal, and gastric cancers, and has expanded its market presence to regions such as the European Union, United Kingdom, and several Asian countries.
Average Trading Volume: 1,558,127
Technical Sentiment Signal: Buy
Current Market Cap: HK$35.03B
For detailed information about 2696 stock, go to TipRanks’ Stock Analysis page.